Determining the societal value of a prospective drug for ME/CFS in Germany.
Gandjour, Afschin·PloS one·2024
This study examined how much money Germany should invest in developing a new ME/CFS drug to provide the greatest benefit to patients and society. Researchers calculated that an effective ME/CFS drug could improve quality of life for thousands of patients and save billions of euros, and they determined that Germany's optimal investment would be around €676 million. The study emphasizes that developing ME/CFS treatments requires countries to work together internationally because no single country can bear the full cost alone.